Panel expects to review five respiratory syncytial virus vaccines and vote on one or two of them in June 2023 and others four months later. Sanofi presents results of three clinical trials of its monoclonal antibody nirsevimab, which is on track to be the second RSV prophylaxis for infants.

With limited supplies of vaccines available, manufacturers are being asked to provide the World Health Organization with their smallpox and monkeypox vaccine research plans, existing stocks of vaccine, and current production capacity.

With more than 1,200 confirmed cases of monkeypox in 28 non-endemic countries and disease incidence also rising in Africa, the WHO and the US CDC have each updated their guidance on the use of antiviral products. The US has just ordered 500,000 more doses of Bavarian Nordic's smallpox vaccine, Jynneos.

GSK has declared success for its RSV vaccine and will begin regulatory talks immediately – but the final efficacy level, as yet unrevealed, could be decisive in a competitive market.